Category IX: Clinical Research

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Adverse Event Management During Treatment with Everolimus plus Exemestane for Postmenopausal Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer (ABC)

Jan Hronek; Lindsay Shelby
Sarah Cannon Research Institute, Nashville, TN 

Background: The combination of the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and the aromatase inhibitor, exemestane, is approved for use in postmenopausal women with HR+, HER2– ABC after failure [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Biomarker Testing in Metastatic Non–Small Cell Lung Cancer: Process Gaps and Best Practices Reported by Nurse Navigators and Nurse Practitioners

Marc Chioda, PharmD1; Ahsan Jamil, PharmD1; Sukriti Kaushal, BS2; Joanne C. Ryan, PhD, RN1
1Pfizer, Inc; 2Atrium Staffing 

Objectives: This study describes the nurse perspective on the importance of biomarker testing for patients with metastatic non–small cell lung cancer (NSCLC) and identifies best practices and process gaps. Background: [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Efficacy and Safety of Ribociclib for the Treatment of Advanced Breast Cancer: A Review of Subgroup Analyses from the Phase 3 Trial MONALEESA-2

Andrea Watson, RN, BSN, OCN
Saint Luke’s Koontz Center for Advanced Breast Cancer, Kansas City, MO 

Background: Endocrine therapy is recommended for patients with hormone receptor–positive (HR+) advanced and metastatic breast cancer without visceral crisis (symptomatic visceral disease). Ribociclib is an orally bioavailable inhibitor of cyclin-dependent [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Evidence-Based Statistics on Complete Prevention and Rapid Sustained Elimination of Chemoradiation Mucositis by ProThelial—97% Reduction in Mucositis

Ricky W. McCullough, MD, MSc
MMI Translational Medicine Clinic and Research Center, Storrs, CT 

Background: Of the 1.6 million individuals annually diagnosed with cancer, 522,166 received chemoradation, with 234,975 developing toxic mucositis and 20% dying within 5 years due largely to mucositis-mediated unplanned treatment [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Frequency of Mutations in Multigene Panel Testing of 324 Ovarian and/or Endometrial Cancer Patients

Lilian Servais, MS, LCGC; Anjali Zimmer, PhD; Jeroen van den Akker, PhD; Will McFadden, PhD;
Alicia Y. Zhou, PhD
Color Genomics, Burlingame, CA 

Background: Endometrial and ovarian cancers are the sixth and seventh most common cancers in women worldwide.1 Inherited germline mutations in genes such as BRCA1 and BRCA2 have been identified in [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Patient-Reported Symptoms Reduce Health-Related Quality of Life Among Patients Undergoing Treatment for Metastatic Cancer

Dana Drzayich Antol, MS1; Adrianne W. Casebeer, PhD, MPP, MS1; Sari Hopson, PhD, MSPH1; Raya Khoury, MPH2; Aparna Parikh, MD2; Alisha Stein, RN-BC, MSN, OCN2; Todd Michael, PharmD, RPh2; Stephen Stemkowski, PhD, MHA1; Mikele Bunce, PhD, MPH2
1Comprehensive Health Insights, Humana, Louisville, KY; 2Genentech, San Francisco, CA 

Background: Symptoms that patients with cancer experience, either due to their illness or as a result of cancer treatment, are known to diminish their health-related quality of life. Objectives: This [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Pooled Analysis of Safety with Extended 3-Year Follow-up Across Combination Dabrafenib and Trametinib (D+T) Phase 3 Trials

Jean-Jacques Grob, MD, PhD1; Keith T. Flaherty, MD2; Georgina V. Long, MD, PhD3; Paul Nathan, MD4; Dirk Schadendorf, MD, PhD5; Antoni Ribas, MD, PhD6; Caroline Robert, MD7; Stephen Lane, MS8; Carmen Mak, PhD8; Bijoyesh Mookerjee, MD8; Michael A. Davies, MD, PhD9
1Aix-Marseille University, Marseille, France; 2Dana-Farber Cancer Institute/Harvard Medical School and Massachusetts General Hospital, Boston, MA; 3Melanoma Institute of Australia and The University of Sydney, Sydney, NSW, Australia; 4Mount Vernon Cancer Centre, Northwood, UK; 5University Hospital of Essen, Essen, Germany; 6UCLA and the Jonsson Comprehensive Cancer Center, Los Angeles, CA; 7Gustave Roussy Comprehensive Cancer Center, Villejuif, Paris-Sud, France; 8Novartis Pharmaceuticals Corporation, East Hanover, NJ; 9The University of Texas MD Anderson Cancer Center, Houston, TX 

Background: Significantly improved outcomes with D+T vs BRAF inhibitor (BRAFi) monotherapy have been demonstrated in phase 3 BRAF V600E/K–mutant mel­anoma trials (COMBI-d [NCT01584648]; COMBI-v [NCT01597908]), supporting use of D+T as [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Single-Agent Ibrutinib in Patients with Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia: The 5-Year Experience

Fan Ny, NP; Jillian Settlemire, RN; Ying Luan, PhD; Alvina D. Chu, MD; Tony Lin; Steven E. Coutre, MD; John C. Byrd, MD
The Ohio State University Comprehensive Cancer Center, Columbus, OH 

Background: Ibrutinib, a B-cell receptor pathway inhibitor, is approved in the United States for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and allows for treatment without [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

The Chimeric Antigen Receptor T-Cell Treatment Journey: Patient and Nursing Education for Managing the ZUMA-1 Pivotal Trial of Axicabtagene Ciloleucel for the Treatment of Aggressive, Refractory Non-Hodgkin Lymphomas

Kathleen McDermott, RN, BSN, OCN, BMTCN1; Amy Patterson, RN2; Nicole Kahle, RN2; Alix Beaupierre, RN, BSN, OCN2; Maritza C. Alencar, DNP, ARNP-BC, BMTCN3
1Dana-Farber Cancer Institute, Boston, MA; 2Moffitt Cancer Center, Tampa, FL; 3Sylvester Comprehensive Cancer Center, Miami, FL 

Background: Chimeric antigen receptor (CAR) T cells are engineered from a patient’s own immune cells to redirect them to attack tumor cells. ZUMA-1 (NCT02348216) evaluated the anti-CD19 CAR T-cell therapy, [ Read More ]

Category IX: Clinical Research, Eighth Annual AONN+ Conference Abstracts

Treatment Options for Premenopausal Women with Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer (ABC)

Jill Schwartz Gomez, RN; Mary Lynn Breslin, RN, BSN, OCN
MD Anderson Cancer Center, Houston, TX 

Background: Breast cancer occurs predominantly in older, postmenopausal women (>50 years), although the incidence of ABC in younger, premenopausal women is increasing.1 Younger patients often experience aggressive disease and are [ Read More ]